Comparative Effectiveness of Beta-Lactams Versus Vancomycin for Treatment of Methicillin-SusceptibleStaphylococcus aureusBloodstream Infections Among 122 Hospitals | Zendy

Jennifer S. McDanel | Zendy; Eli N. Perencevich | Zendy; Daniel J. Diekema | Zendy; Loreen A. Herwaldt | Zendy; Tara C. Smith | Zendy; Elizabeth A. Chrischilles | Zendy; Jeffrey D. Dawson | Zendy; Lan Jiang | Zendy; Michihiko Goto | Zendy; Marin L. Schweizer | Zendy

Open Access

Comparative Effectiveness of Beta-Lactams Versus Vancomycin for Treatment of Methicillin-SusceptibleStaphylococcus aureusBloodstream Infections Among 122 Hospitals

Author(s) -

Jennifer S. McDanel,

Eli N. Perencevich,

Daniel J. Diekema,

Loreen A. Herwaldt,

Tara C. Smith,

Elizabeth A. Chrischilles,

Jeffrey D. Dawson,

Lan Jiang,

Michihiko Goto,

Marin L. Schweizer

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ308

Subject(s) - medicine , vancomycin , cefazolin , hazard ratio , empiric therapy , bacteremia , staphylococcus aureus , blood culture , retrospective cohort study , antibiotics , surgery , confidence interval , microbiology and biotechnology , alternative medicine , pathology , biology , bacteria , genetics

Previous studies indicate that vancomycin is inferior to beta-lactams for treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections. However, it is unclear if this association is true for empiric and definitive therapy. Here, we compared beta-lactams with vancomycin for empiric and definitive therapy of MSSA bloodstream infections among patients admitted to 122 hospitals.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research